The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The efficacy ofSilybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial
Abstract
Oxidative stresses are increasingly implicated in the pathogenesis of diabetic complications which may either cause direct pancreatic beta-cell damage or lead to metabolic abnormalities that can induce or aggravate diabetes. The valuable effect of antioxidant nutrients on the glycemic control of diabetic patients has been reported in experimental and clinical studies. The present study was designed to investigate the effects of the herbal medicine, Silybum marianum seed extract (silymarin), which is known to have antioxidant properties on the glycemic profile in diabetic patients. A 4-month randomized double-blind clinical trial was conducted in 51 type II diabetic patients in two well-matched groups. The first group (n = 25) received a silymarin (200 mg) tablet 3 times a day plus conventional therapy. The second group (n = 26) received the same therapy but a placebo tablet instead of silymarin. The patients were visited monthly and glycosylated hemoglobin (HbA(1)c), fasting blood glucose (FBS), insulin, total cholesterol, LDL and HDL, triglyceride, SGOT and SGPT levels were determined at the beginning and the end of the study. The results showed a significant decrease in HbA(1)c, FBS, total cholesterol, LDL, triglyceride SGOT and SGPT levels in silymarin treated patients compared with placebo as well as with values at the beginning of the study in each group. In conclusion, silymarin treatment in type II diabetic patients for 4 months has a beneficial effect on improving the glycemic profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
Boden, G. (1997) · Diabetes · doi:10.2337/diab.46.1.3 · Cited by 1,728
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Milk Thistle (Silybum marianum) for the Therapy of Liver Disease
Flora, K. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(97)00082-8 · Cited by 746
Maddux, B. A., See, W., Lawrence, J. C., Goldfine, A. L., Goldfine, I. D., & Evans, J. L. (2001) · Diabetes · doi:10.2337/diabetes.50.2.404 · Cited by 405
Evans, J. L., & Goldfine, I. D. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050194279 · Cited by 228
Velussi, M., Cernigoi, A. M., Ariella, D. M., Dapas, F., Caffau, C., & Zilli, M. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80255-3 · Cited by 216
Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas
Soto, C., Recoba, R., Barrón, H., Alvarez, C., & Favari, L. (2003) · Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology · doi:10.1016/s1532-0456(03)00214-x · Cited by 188
Milk thistle: Silybum marianum
Pepping, J. (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.12.1195 · Cited by 153
Rudich, A., Tirosh, A., Potashnik, R., Khamaisi, M., & Bashan, N. (1999) · Diabetologia · doi:10.1007/s001250051253 · Cited by 147
Tsuzura, S., Ikeda, Y., Suehiro, T., Ota, K., Osaki, F., Arii, K., Kumon, Y., & Hashimoto, K. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.009 · Cited by 119
Prevention of Alloxan-Induced Diabetes Mellitus in the Rat by Silymarin
Soto, C. P., Perez, B. L., Favari, L., & Reyes, J. L. (1998) · Comparative Biochemistry and Physiology Part C Pharmacology Toxicology and Endocrinology · doi:10.1016/s0742-8413(97)00198-9 · Cited by 119
Silymarin induces recovery of pancreatic function after alloxan damage in rats
Soto, C., Mena, R., Luna, J., Cerbón, M. A., Larrieta, E., Vital, P., Uría-Galicia, E., Sánchez, M., Recoba, R., Barrón, H., et al. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.04.019 · Cited by 112
Antioxidants in Diabetes Management
Rosen, P., Tritschler, H., King, G. A., & Azzi, A. (2000) · CRC Press eBooks · doi:10.1201/9781482277326 · Cited by 90
Lirussi, F., Beccarello, A., Zanette, G., Monte, A. D., Donadon, V., Velussi, M., & Crepaldi, G. (2002) · PubMed · Cited by 88
Sonnenbichler, J., Goldbero, M., Hane, L., Madubunyi, I. I., Vogl, S., & Isolde, Z. E. T. L. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90233-9 · Cited by 85
Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro
Škottová, N., Krecman, V., & Šimánek, V. (1999) · Phytotherapy Research · doi:10.1002/(sici)1099-1573(199909)13:6<535::aid-ptr526>3.0.co;2-w · Cited by 53
Velussi, M., Cernigoi, A. M., Viezzoli, L., Dapas, F., Caffau, C., & Zilli, M. (1993) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80660-5 · Cited by 36
Cited by
Alterio, V., Di Fiore, A., D’Ambrosio, K., Supuran, C. T., & De Simone, G. (2012) · Chemical Reviews · doi:10.1021/cr200176r · Cited by 1,238
Silybin and the liver: From basic research to clinical practice
Loguercio, C. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i18.2288 · Cited by 375
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Chang, C. L. T., Lin, Y., Bartolome, A. P., Chen, Y.-C., Chiu, S.-C., & Yang, W.-C. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/378657 · Cited by 274
Loguercio, C., Andreone, P., Brisc, C., Brisc, M. C., Bugianesi, E., Chiaramonte, M., Cursaro, C., Danila, M., de Sio, I., Floreani, A., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.008 · Cited by 267
Metadata
- Authors
- Huseini, H. F., Larijani, B., Heshmat, R., Fakhrzadeh, H., Radjabipour, B., Toliat, T., & Raza, M.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2006
- Volume
- 20
- Issue
- 12
- Pages
- 1036-1039
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W2117701880
- Cited by
- 262
- References
- 18
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.